Pancreatic Cancer Research

ResearcherRoswell Park Comprehensive Cancer CenterActive in the last 2 years

Wells A. Messersmith

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2349-0885; OpenAlex author ID A5078259926. Sources: ClinicalTrials.gov.

Their work

Papers
37 (first author 2, last author 7)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
2
Collaborators
132
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: none · 2014: 1 paper · 2015: 2 papers · 2016: 1 paper, 1 trial · 2017: 2 papers, 1 trial · 2018: 2 papers · 2019: none · 2020: 2 papers · 2021: 6 papers · 2022: 1 paper · 2023: 4 papers · 2024: 4 papers · 2025: 5 papers · 2026: 3 papers

Papers 37

  1. Neoadjuvant multiagent chemotherapy or upfront surgery for primary resectable pancreatic cancer - A retrospective intention-to-treat analysis. Co-author DOI 10.1016/j.hpb.2026.04.451↗
  2. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  3. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Co-author DOI 10.1093/bjsopen/zrag057↗
  4. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  5. Pancreatic Cancer Progression Involves Increased Lysyl Oxidase-Mediated Collagen Cross-Links as Part of the Desmoplastic Reaction. Co-author DOI 10.1021/acs.biochem.5c00125↗
  6. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  7. Oligometastatic pancreatic cancer: current state of management and emerging therapies. Co-author DOI 10.1093/oncolo/oyaf154↗
  8. Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study. Co-author DOI 10.1093/oncolo/oyaf271↗
  9. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  10. A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreat… Co-author DOI 10.1016/j.ejca.2024.113950↗
  11. A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-0499↗
  12. Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL). Co-author DOI 10.1371/journal.pone.0298808↗
  13. Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP … Last author DOI 10.1016/j.esmoop.2023.101584↗
  14. Pulmonary metastasectomy is associated with survival after lung-only recurrence in pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.05.008↗
  15. Advances in the management of pancreatic cancer. Last author DOI 10.1136/bmj-2022-073995↗
  16. Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment. Co-author DOI 10.1158/2767-9764.crc-23-0065↗
  17. Targeting Treg-Expressed STAT3 Enhances NK-Mediated Surveillance of Metastasis and Improves Therapeutic Response in Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-2767↗
  18. Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleoti… Co-author DOI 10.1007/s00262-020-02701-w↗
  19. Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreati… Co-author DOI 10.1016/j.hpb.2020.11.004↗
  20. Outcome of neoadjuvant treatment for pancreatic cancer in elderly patients: comparative, observational cohort study. Co-author DOI 10.1093/bjs/znab092↗
  21. Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchyal Transition in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-3892↗
  22. Neoadjuvant treatment of localized pancreatic adenocarcinoma. First author DOI 10.21037/jgo-20-250↗
  23. WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.642328↗
  24. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated … Co-author DOI 10.1007/s10637-019-00824-1↗
  25. Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-0489↗
  26. Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models. Co-author DOI 10.2174/2212697x05666180516120907↗
  27. Perioperative and Survival Outcomes Following Neoadjuvant FOLFIRINOX versus Gemcitabine Abraxane in Patients with Pancreatic Adenocarcinoma. Co-author PMID 29950957↗
  28. A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing … Co-author DOI 10.1007/s10637-017-0473-9↗
  29. Patterns of Care for Locally Advanced Pancreatic Adenocarcinoma Using the National Cancer Database. Co-author DOI 10.1097/mpa.0000000000000876↗
  30. Aldehyde Dehydrogenase 1B1 as a Modulator of Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000542↗
  31. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreate… Last author DOI 10.1093/annonc/mdv264↗
  32. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreate… Last author DOI 10.1093/annonc/mdv477↗
  33. A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. Last author DOI 10.1007/s10637-014-0083-8↗
  34. Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreati… Last author DOI 10.1002/cam4.27↗
  35. Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with soli… First author DOI 10.1158/1078-0432.ccr-11-2813↗
  36. Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer. Co-author DOI 10.1593/neo.111810↗
  37. Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. Last author DOI 10.1007/s10637-010-9413-7↗

Trials 2

  1. A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection Principal investigator NCT03038477↗
  2. Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates Principal investigator NCT02723331↗

Closest collaborators

The 25 strongest of 132 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marco Del Chiaro · 10 shared papers, 2021–2026 · strength 1.70
  2. Christopher Hanyoung Lieu · 8 shared papers, 2017–2025 · strength 1.28
  3. Richard David Schulick · 9 shared papers, 2018–2026 · strength 1.23
  4. Toshitaka Sugawara · 4 shared papers, 2023–2026 · strength 0.89
  5. Sana D. Karam · 6 shared papers, 2021–2023 · strength 0.82
  6. Alexis Diane Leal · 5 shared papers, 2021–2024 · strength 0.76
  7. Todd M. Pitts · 5 shared papers, 2018–2025 · strength 0.76
  8. Robert William Lentz · 3 shared papers, 2023–2025 · strength 0.61
  9. Karyn A. Goodman · 6 shared papers, 2017–2022 · strength 0.59
  10. Colin D. Weekes · 6 shared papers, 2011–2025 · strength 0.47
  11. Oskar Franklin · 2 shared papers, 2026 · strength 0.46
  12. Thomas F. Stoop · 2 shared papers, 2026 · strength 0.46
  13. Miles Piper · 4 shared papers, 2021–2023 · strength 0.45
  14. Kirk Charles Hansen · 3 shared papers, 2021–2025 · strength 0.43
  15. Adam Christopher Mueller · 4 shared papers, 2021–2022 · strength 0.43
  16. John J. Arcaroli · 6 shared papers, 2012–2024 · strength 0.40
  17. Sarah Lindsey Davis · 4 shared papers, 2017–2021 · strength 0.38
  18. Ana Gleisner · 3 shared papers, 2018–2023 · strength 0.34
  19. Mark M. Zalupski · 2 shared papers, 2024 · strength 0.32
  20. Sarah J. Hartman · 2 shared papers, 2021–2024 · strength 0.29
  21. Deirdre Jill Cohen · 3 shared papers, 2015–2025 · strength 0.29
  22. Aaron James Scott · 3 shared papers, 2015–2025 · strength 0.29
  23. Martin D. McCarter · 3 shared papers, 2018–2021 · strength 0.29
  24. Andrii Khomiak · 1 shared paper, 2025 · strength 0.28
  25. Atsushi Oba · 2 shared papers, 2021–2026 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.